Weight-loss drug semaglutide reduces heavy alcohol drinking in new clinical trial A new clinical trial reveals that a popular weight-loss medication helps people with both obesity and alcohol use disorder reduce their frequency of heavy drinking
Considerations and Future Research While the early research on BPC-157 is promising, more studies are needed to fully understand its long-term effects and safety profile
Furthermore, exploring novel delivery systems, such as the proposed cepharanthine-selenium polymer, could enhance bioavailability and therapeutic efficacy
Acute Kidney Injury: Some individuals may experience a decline in kidney function while taking semaglutide
In particular, expression quantitative trait loci (eQTL) and protein quantitative trait loci (pQTL) analyses have emerged as powerful tools for identifying disease-associated genetic variants ( Building upon this, Mendelian randomization (MR), a causal inference method based on genetic variation, can effectively overcome confounding and reverse causation issues commonly seen in observational studies